Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to $17.9 million.

  • Bolt Biotherapeutics' Cash from Investing Activities rose 435.29% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.5 million, marking a year-over-year decrease of 930.94%. This contributed to the annual value of $57.6 million for FY2024, which is 1895.04% down from last year.
  • According to the latest figures from Q3 2025, Bolt Biotherapeutics' Cash from Investing Activities is $17.9 million, which was up 435.29% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Cash from Investing Activities registered a high of $40.8 million during Q1 2022, and its lowest value of -$190.5 million during Q1 2021.
  • Over the past 5 years, Bolt Biotherapeutics' median Cash from Investing Activities value was $13.6 million (recorded in 2023), while the average stood at -$131421.1.
  • Per our database at Business Quant, Bolt Biotherapeutics' Cash from Investing Activities plummeted by 130006.61% in 2021 and then skyrocketed by 166451.61% in 2023.
  • Bolt Biotherapeutics' Cash from Investing Activities (Quarter) stood at $21.0 million in 2021, then dropped by 21.86% to $16.4 million in 2022, then dropped by 3.81% to $15.8 million in 2023, then fell by 22.63% to $12.2 million in 2024, then surged by 46.21% to $17.9 million in 2025.
  • Its last three reported values are $17.9 million in Q3 2025, $10.8 million for Q2 2025, and $14.6 million during Q1 2025.